Welcome to our dedicated page for Medicinova SEC filings (Ticker: MNOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MediciNova, Inc. filings document a clinical-stage biopharmaceutical issuer developing MN-166 and MN-001 across neurological, inflammatory, fibrotic, and metabolic disease programs. Annual and event filings describe reported financial results, including preliminary unaudited results furnished through a Japanese Kessan Tanshin, and securities registration materials for common stock offerings.
Proxy and 8-K filings cover MediciNova's Delaware corporate governance, director elections, executive compensation, equity awards, stockholder voting results, and Nasdaq-listed common stock. The filing record also provides formal disclosure around capital structure, risk factors, material events, and governance matters tied to the company's drug-development business.
MediciNova Inc. director Nagao Hideki received a grant of 44,500 stock options for Common Stock. The options have an exercise price of $1.36 per share and expire on June 22, 2036. Following this grant, Nagao holds 44,500 stock options directly.
The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the company. This is a compensation-related award rather than an open-market purchase or sale.
MediciNova Inc. director Nicole Lemerond received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $1.36 per share and expire on June 22, 2036. They vest in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, contingent on her continued service with the company.
MediciNova Inc. director Carolyn Beaver received a stock option grant covering 44,500 shares of common stock. The options have an exercise price of $1.36 per share and expire on June 22, 2036. The award vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, subject to her continued service with the company. After this grant, she holds 44,500 derivative securities (options). This is a compensation-related award rather than an open-market share purchase or sale.
MediciNova, Inc. reported results from its 2026 annual meeting of stockholders held on June 23, 2026. As of the April 24, 2026 record date, the company had 49,221,246 shares of common stock outstanding, and 29,774,819 shares were represented in person or by proxy, establishing a quorum.
Two director nominees, Hikedi Nagao and Nicole Lemerond, each received more votes "For" than "Against," with substantial broker non-votes recorded. Three additional proposals also showed more "For" than "Against" votes, based on totals of 26,697,794 vs. 1,911,245; 22,156,922 vs. 6,432,457; and 22,656,038 vs. 5,805,893, respectively.
MediciNova reported another operating loss for the quarter ended March 31, 2026 as it continues to invest in its pipeline. Revenue was $186,984, up from zero a year earlier, reflecting services under its Mayo ALS research agreement. Operating expenses were $3.0 million, slightly lower than $3.2 million in 2025 as research, development and patent costs declined to $1.3 million while general and administrative expenses rose to $1.6 million.
Net loss narrowed to $2.6 million, or $0.05 per share, compared with a $2.9 million loss, or $0.06 per share, a year earlier. Cash and cash equivalents were $27.3 million at March 31, 2026, down from $36.6 million a year ago, after $3.5 million of operating cash outflows in the quarter.
Management continues to focus on developing MN-166 (ibudilast) for several neurological indications and MN-001 (tipelukast) for fibrotic and metabolic diseases. The company reports working capital of $25.1 million and believes its current cash resources can fund operations at least through May 2027.
MediciNova, Inc. has called its 2026 Annual Meeting for June 23, 2026 in La Jolla, California. Stockholders will vote on electing two Class I directors, ratifying BDO USA, P.C. as auditor, and approving a major increase in authorized common stock.
The company proposes amending its Restated Certificate of Incorporation to raise authorized common shares from 100,000,000 to 247,000,000, while keeping preferred stock at 3,000,000 shares. As of April 24, 2026, 49,221,246 common shares were outstanding, with additional shares reserved for equity plans.
MediciNova, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held on June 23, 2026 in La Jolla, California. The notice/ proxy materials are expected to be mailed on or around April [ ], 2026 and the record date for voting is April 24, 2026.
Stockholders will vote to (1) elect two Class I directors (Hideki Nagao and Nicole Lemerond), (2) ratify BDO USA, P.C. as independent auditors for fiscal 2026, (3) approve an increase in authorized common stock from 100,000,000 to 247,000,000 shares, (4) approve adjournment authority to permit further solicitation, and (5) transact other business properly brought before the meeting.
MediciNova, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held June 23, 2026 at 1:00 p.m. PDT in La Jolla, California. Stockholders of record as of April 24, 2026 may vote on: election of two Class I directors; ratification of BDO USA, P.C. as independent auditors; an amendment to increase authorized common stock from 100,000,000 to 247,000,000 shares; and a proposal to permit adjournment for further solicitation. The proxy materials and the 2025 Annual Report will be furnished primarily via the Internet and are available at the listed proxy website.
MediciNova, Inc. files its annual report describing a late‑stage biopharmaceutical pipeline built around two lead drug candidates, MN‑166 (ibudilast) and MN‑001 (tipelukast). The company focuses on serious diseases with high unmet need, including progressive multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, degenerative cervical myelopathy, ARDS in COVID‑19, and NASH/NAFLD with metabolic disorders.
MN‑166 has Fast Track designations in progressive MS and ALS and Orphan‑Drug designations in ALS and glioblastoma, supported by multiple Phase 2 and Phase 2b/3 trials and extensive preclinical data. MN‑001 targets fibrotic and metabolic liver disease, with Fast Track for NASH with fibrosis and positive Phase 2 and preclinical results in triglyceride reduction and anti‑fibrotic effects. The report notes continued operating losses, no approved commercial products, dependence on external manufacturing and strategic partners, and significant clinical, regulatory, and market competition risks.